Transcripta Bio utilizes a proprietary Drug-Gene Atlas and Conductor AI to map molecular structures and predict gene expression responses to billions of compounds, enabling rapid identification of therapeutic candidates. This approach accelerates drug discovery by providing high certainty in targeting gene expression across multiple diseases, significantly reducing the time and risk associated with traditional methods.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods are slow, expensive, and have a high failure rate due to the complexity of predicting how drugs will affect gene expression across multiple diseases. Existing approaches often lack the ability to rapidly screen and validate potential therapeutic candidates with high certainty.
Solution
Transcripta Bio has developed a platform that combines a proprietary Drug-Gene Atlas with Conductor AI to accelerate drug discovery. The Drug-Gene Atlas maps the effects of thousands of compounds on gene expression, while Conductor AI predicts gene expression responses to billions of novel compounds. This enables the rapid identification of therapeutic candidates that rebalance gene expression to treat disease. The platform virtually screens billions of compounds for disease-modifying ability and off-target effects, and then synthesizes and tests new candidates in its lab to identify and de-risk novel therapies.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.
Features
- Drug-Gene Atlas: Maps molecular structure and drug action to the whole cell transcriptome.
- Conductor AI: An AI modeling suite that discovers and predicts the effects of new drugs at transcriptome scale.
- Virtual Screening: Screens billions of compounds for disease-modifying ability and off-target effects.
- High-throughput Screening: Screens thousands of molecules across 20,000 genes to map chemical structure to gene expression.
- Rapid Synthesis and Testing: Quickly synthesizes and tests new candidates in its lab to identify and de-risk novel therapies.
- Target Certainty: Provides high target certainty with hard genetic evidence.